BramhAnsh Technologies Pvt. Ltd., supported by DRISHTI CPS under the Seed Support scheme, has developed a solution for migraine sufferers. Their innovative product, Migraelief, is a drug-free wearable neurostimulation device that provides both immediate relief and prevention for migraines. This advanced technology addresses the growing global challenge of migraines, which has become the third most prevalent illness worldwide, affecting millions of people.
Migraelief stands out in the market with its unique approach to migraine treatment. Unlike traditional methods that rely heavily on chemical drugs and their associated side effects, Migraelief uses neurostimulation to target the root cause of migraines. The device works by sending sound vibration waves through the skull, tissues, and cells of the brain, effectively stimulating nerves to provide relief. With an impressive efficiency rate of over 80% and no reported side effects, Migraelief offers a safe and effective alternative to conventional treatments.
The impact of Migraelief has been significant, as demonstrated by clinical trials involving over 500 participants. An impressive 75% of users reported decreased headache intensity and improved sleep quality, highlighting the device’s effectiveness in both acute treatment and prevention of migraines. The user-friendly design, coupled with an AI-powered app for easy operation, makes Migraelief accessible to a wide range of users seeking a non-pharmacological solution to their migraine problems.
With the support of DRISHTI CPS in crucial funding, mentorship, and networking opportunities, BramhAnsh is well-positioned to make a lasting impact on global health. As BramhAnsh Technologies continues to gather data and explore partnerships with healthcare providers and wellness centers, Migraelief offers new hope to millions of people who suffer from migraines, aiming to make their lives better and easier.
Why we invested in BramhAnsh- Our decision was driven by several key factors, including the innovative approach to a widespread health issue and the strong technical expertise of the founding and advisory team. We saw in Migraelief a solution that not only addresses a critical medical need but also aligns with the growing demand for non-invasive, drug-free treatments. The global applicability of this technology, coupled with its potential to significantly improve quality of life for millions, made BramhAnsh an compelling investment opportunity. Through our support, we aim to accelerate BramhAnsh’s growth and help bring this transformative technology to those in need worldwide.